Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (4255)	3/8/2000 11:25:00 AM
From: Don Miller	Read Replies (2) \| Respond to of 10280

No News?? For emphasis-- * "More than 15 abstracts were presented on SEPR's DCL, Xopenex, norastemizole, and formoterol at this past weekend's American Academy of Allergy, Asthma, and Immunology meeting. The majority of the data focused on DCL, Sepracor and partner Schering-Plough's second-generation Claritin. We believe the data indicates that DCL is a safe, well-tolerated, and potent H1 receptor antagonist. Partner Schering-Plough has filed an NDA for DCL, and we anticipate approval in late 2000. Head-to-head chamber study data appear to indicate that SEPR's norastemizole has a superior onset of action (OA) compared to Schering's currently marketed Claritin. More specifically, norastemizole has 20-minute OA compared to Claritin's 140 minutes. Xopenex Grand Symposia and additional clinical data could be incrementally positive to marketing efforts for the prdouct." Ed, at least 5 or more of these abstracts were presented and commented upon by posters more technically proficient than myself, in the YC. Their conclusions were generally positive, but no block buster results. May be "they" were expecting a positive surprise. Considering this conference concluded 3/6 the stock reaction has been poor. It seems we simultaneously had the full amount of the recent funding option converted in the last few days as well.